Alzheimer's disease is a devastating illness, and unfortunately a cure has been elusive. A drug being developed by Johnson & Johnson (NYSE: JNJ), Pfizer (NYSE: PFE), and Elan (NYSE: ELN) called bapineuzumab was scraped over the summer after failing to satisfy its phase 3 clinical trial endpoints. Eli Lilly's (NYSE: LLY) drug, solanezumab, also failed to meet the goals set for its late-stage study. While combining the results from the two solanezumab phase 3 trials did show some positive results and briefly generated investor excitement, there is some skepticism that the drug will gain Food and Drug Administration approval.

Today, it looks like there's a new player in the fight to treat Alzheimer's; powerhouse pharma company Merck (NYSE: MRK) announced that it's bringing its experimental drug MK-8931 to phase 2/3 trials. In the following video, health care analysts Max Macaluso and Brenton Flynn break down the details for investors.

Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying calls on Johnson & Johnson. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.